Retatrutide vs Adipotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In phase 2 it produced about 24 percent weight loss at the top dose, and in the phase 3 TRIUMPH-1 trial Lilly reported 28.3 percent at 12 mg over 80 weeks. It is investigational, made by Eli Lilly, and not FDA approved; Lilly plans to file with the FDA in the first quarter of 2027. Because it is not an approved drug, FDA says it cannot be legally compounded.
Also: FTPP, Fat-Targeted Proapoptotic Peptide
Adipotide is an experimental peptide built to kill fat tissue by cutting off its blood supply. One half homes in on prohibitin, a protein on the blood vessels that feed white fat, and the other half is a cell-killing sequence that triggers those vessel cells to self-destruct. It produced striking weight loss in obese mice and monkeys, but it also caused kidney damage in every primate species tested, and its only human trial was terminated after enrolling 4 people with no results ever posted.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Retatrutide has stronger research evidence (Human Trials) compared to Adipotide (Animal Studies).
Detailed Comparison
| Attribute | Retatrutide | Adipotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. | The molecule has two parts joined together. The targeting part, CKGGRAKDC, was found by screening peptides in living mice for ones that stick to fat-tissue blood vessels; it binds prohibitin on the endothelial cells lining white fat vasculature. The payload, D(KLAKLAK)2, is a known pro-apoptotic peptide that disrupts mitochondrial membranes once inside a cell, setting off programmed cell death. Kill the vessels and the fat tissue they supply is starved and resorbed. This is a destructive mechanism, not a metabolic nudge like GLP-1 drugs, and that matters for safety: prohibitin is not exclusive to fat vessels, and the kidney's proximal tubule cells turned out to be a clear off-target casualty in monkeys. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | No established human dose Once daily in animal studies |
| Administration | Subcutaneous injection weekly | Subcutaneous injection |
| Typical Duration | Long-term use expected | 28 days in the main monkey efficacy study; up to 63 days in dose-escalation |
| Best Time to Take | Morning, same day each week | No evidence-based timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The first big human evidence was the phase 2 trial by Jastreboff and colleagues (New England Journal of Medicine, 2023), which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48. In a liver-fat substudy of 98 participants, liver fat dropped by about 81 to 82 percent at the 8 and 12 mg doses by week 24. Phase 3 has since read out: in TRIUMPH-1, Lilly reported mean weight loss of 19.0, 25.9 and 28.3 percent at 4, 9 and 12 mg over 80 weeks versus 2.2 percent on placebo (efficacy estimand, which assumes people stayed on the drug; analyses counting everyone randomized come out a few points lower). TRIUMPH-2 (type 2 diabetes plus obesity) reached about 20.8 percent at 12 mg, and TRIUMPH-3 (severe obesity plus heart disease) about 22.6 percent. Side effects were dominated by dose-dependent gastrointestinal issues like nausea, vomiting, and diarrhea, plus a dysesthesia (skin sensitivity) signal at the top dose. Retatrutide sold outside of trials is not an approved, quality-controlled medicine. | The concept came from Kolonin and colleagues (Nature Medicine, 2004), who reported that ablating fat vasculature reversed obesity in mice. The key primate study is Barnhart et al. (Science Translational Medicine, 2011) from MD Anderson. Obese rhesus monkeys given 0.43 mg/kg/day subcutaneously for 28 days lost 7.4% to 14.7% of body weight (average 10.6%) while controls stayed roughly flat, with MRI and DEXA confirming fat loss and clear improvements in insulin resistance. Lean monkeys at the same dose did not lose weight. The cost: serum creatinine rose in a dose-dependent way above 0.25 mg/kg, and the authors documented kidney tubule injury with glucose and protein in the urine, dehydration at higher doses, and low phosphorus and potassium. Most of it reversed within 28 days, but one treated monkey in each study still had residual changes. A first-in-human phase I trial at MD Anderson in obese men with metastatic prostate cancer (NCT01262664) started in 2012, enrolled only 4 patients, and was terminated at the investigator's request in 2019 with no results posted. That is the whole human record. Nobody knows the safe human dose, and the kidney signal is the opposite of reassuring. |
Frequently Asked Questions: Retatrutide vs Adipotide
What is the difference between Retatrutide and Adipotide?
Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in phase 2 it produced about 24 percent weight loss at the top dose, and in the phase 3 triumph-1 trial lilly reported 28.3 percent at 12 mg over 80 weeks. it is investigational, made by eli lilly, and not fda approved; lilly plans to file with the fda in the first quarter of 2027. because it is not an approved drug, fda says it cannot be legally compounded. Adipotide is a weight loss peptide that adipotide is an experimental peptide built to kill fat tissue by cutting off its blood supply. one half homes in on prohibitin, a protein on the blood vessels that feed white fat, and the other half is a cell-killing sequence that triggers those vessel cells to self-destruct. it produced striking weight loss in obese mice and monkeys, but it also caused kidney damage in every primate species tested, and its only human trial was terminated after enrolling 4 people with no results ever posted. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Adipotide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Adipotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Adipotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Adipotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.